CHERIE BAHM: Open Payments
NPI 1366959330 · ARKANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,037 in 65 payments from 20 companies in 2025. Trend: 2023 $226 · 2024 $884 · 2025 $1,037
Food & beverage: $1,037
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $162 |
| Novo Nordisk Inc | 8 | $143 |
| ABBVIE INC. | 11 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $92 |
| PFIZER INC. | 5 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Abbott Laboratories | 2 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
Products named: QULIPTA, MOUNJARO, Wegovy, CAPLYTA, FANAPT, FREESTYLE LIBRE 3, XIFAXAN, Ozempic.
Industry payments across KS — which companies pay providers there.
